Detailed Information on Publication Record
2011
Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen
SZTURZ, Petr, Zdeněk ADAM, Mária KLINCOVÁ, Josef FEIT, Marta KREJČÍ et. al.Basic information
Original name
Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen
Authors
SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Mária KLINCOVÁ (703 Slovakia, belonging to the institution), Josef FEIT (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Lenka ZAHRADOVÁ (203 Czech Republic, belonging to the institution), Vladimír VAŠKŮ (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)
Edition
Clinical Lymphoma, Myeloma & Leukemia, 2011, 2152-2650
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.880
RIV identification code
RIV/00216224:14110/11:00054365
Organization unit
Faculty of Medicine
UT WoS
000298280200010
Keywords in English
Autoimmunity; Bortezomib; IgA pemphigus; Lenalidomide; Multiple myeloma; Paraproteinemia
Tags
International impact
Změněno: 12/10/2012 19:11, doc. MUDr. Petr Szturz, Ph.D.
Abstract
V originále
Generally, monoclonal immunoglobulins do not bind an autologous antigen, except for some cases, when it causes immune damage to body’s own tissues. Vesiculopustulous dermatitis associated with immunoglobulin (Ig) A deposition in the epidermis represents an autoimmune skin manifestation of monoclonal gammopathy. It is commonly referred to as subcorneal pustular dermatosis type of IgA pemphigus.1 In our previous work, we reported on complete and long-term remission of multiple myeloma associated IgA pemphigus after treatment with a bortezomib (Velcade) based regimen.2 In this work, to our knowledge, we are the first to publish a convincing clinical remission and excellent drug tolerance of a subsequent lenalidomide (Revlimid) based regimen used in the same patient for management of the relapsed disease.
Links
| LC06027, research and development project |
| ||
| MSM0021622434, plan (intention) |
| ||
| NT11154, research and development project |
|